ClinicalTrials.gg
Active, not recruitingNCT05946629Updated Sep 24, 2026

SELUTION 4 De Novo Small Vessel IDE Trial

An interventional study of PCI with SELUTION SLR DCB and PCI with FDA approved "-limus" DES in Coronary Artery Disease, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 70 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
960
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Planned enrollment
110th of 745
960 · median 107
Started
2023
with 28 others
No phase
352 of 1,104
41 open now
Primary completion
2027-09
later than 81 of 141 live
Registered
1,000th of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 110th largest by planned enrollment of the 745 interventional ones that give a count, is one of 29 that started in 2023, is one of 352 with no phase, reaches primary completion later than 81 of the 141 other live ones, and was the 1,000th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA.

The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Read the detailed description

Prospective, randomized controlled, single-blind, multicenter, clinical trial

The study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.

Subjects who present with chronic coronary syndrome (CCS), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) with an indication for percutaneous coronary intervention (PCI) with planned intervention for de novo lesions in small coronary vessels (RVD 2.00 mm to 2.75 mm) and meeting all eligibility criteria will be randomized 1:1 to treatment of the identified target lesion with either the SELUTION SLR 014 PTCA DEB or contemporary DES.

Randomized Cohort:

  • Intervention (DEB Strategy): Subjects randomized to the SELUTION SLR 014 PTCA DEB arm will receive lesion preparation according to the 3rd drug coated balloon (DCB) consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, intravascular lithotripsy, laser, rotational or orbital atherectomy, cutting or scoring balloon at the discretion of the operator as needed to reduce diameter stenosis to ≤ 30%). Subjects with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30%) will receive a DES instead of the SELUTION DEB but remain in the SELUTION DEB group (intention to treat analysis). The DEB should not be used after DES implant.
  • Control (DES): Subjects randomized to the DES arm will receive treatment using any FDA approved "limus-based" DES, as per standard institutional practice.

Angiographic Substudy:

The angiographic substudy is a parallel registry consisting of up to 30 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. These subjects will undergo angiography at 12 months post-procedure. Clinical follow-up will not extend beyond 12 months in this cohort.

Pharmacokinetic (pK) Substudy:

The pKsubstudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. This study will be conducted under an approved substudy protocol and will include blood draws at regular intervals to characterize the pK plasma profile of sirolimus.

Primary Endpoint:

Target lesion failure (TLF), defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • CAD
  • DCB
  • DEB
  • NSTEMI
  • Stable Angina
  • Chronic Coronary Syndrome
  • CCS
  • Drug Coated Balloons
  • Drug Eluting Balloons
  • Small Vessels
  • SELUTIONSLR
  • Sirolimus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Inclusion Criteria

Subjects must meet all of the following clinical criteria to participate in the trial:

  1. Subject is ≥ 18 years (or the minimum legal age as required by local regulations).
  2. Female subjects of must have a negative pregnancy test ≤ 7 days before the procedure or are using a device or drug.
  3. Subject presents with chronic coronary syndromes [CCS] (manifest as documented angina or positive functional testing), unstable angina or stabilized non-ST elevation myocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with an indication for PCI and planned intervention.
  4. Subject can tolerate dual antiplatelet therapy with aspirin, plus either Clopidogrel, Prasugrel, or Ticagrelor. (Note: For subjects requiring oral anticoagulation, aspirin may be omitted based on investigator discretion).
  5. Subject has > 1 year in the opinion of the investigator.
  6. Subject is willing and able to provide and comply with study procedures and required follow-up evaluations.

PK Sub- Study Inclusion Criteria:

Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:

1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.

Imaging Inclusion Criteria

Subject's target lesion(s) must meet all of the following angiographic criteria for the subject to participate in the trial:

  1. A single, target lesions that meet criteria can be treated in a single vessel. No non-target lesions can be treated within the target vessel in the index procedure. Non-target lesions within the target vessel can be staged for treatment > 30 days from the index procedure.
  2. Up to two (2) non-target lesions in up to two (2) non-target vessels may be treated, but successful PCI of the non-target lesions must be completed before randomization and treatment of the target lesion.
  3. Target lesion is ≤ 36 mm in length.
  4. Target lesion has diameter stenosis > 50% and ≤ 99% with distal flow at least thrombolysis in myocardial infarction (TIMI) 2.
  5. Target vessel has RVD of ≥ 2.00 mm and ≤ 2.75 mm [by visual assessment].
  6. Target lesion is within a native coronary artery or major branch.
  7. A target lesion within a bifurcation is allowed only if a single vessel (either main vessel or side branch) is to be treated.
  8. The identified target lesion has high probability for successful treatment with approved pre-treatment techniques and DEB alone based on Investigator assessment.

Exclusion criteria

Exclusion Criteria:

  • Clinical Exclusion Criteria

Subjects who meet any of the following clinical criteria will be excluded from the trial:

  1. Subject with known or allergy to Sirolimus or its analogues.
  2. Subject presents with NSTEMI and rising biomarkers, or ongoing chest pain or is hemodynamically instable.
  3. Subject with history of ST-elevation myocardial infarction (STEMI) within 30 days of the index procedure.
  4. Subject with planned major surgery within 30 days following the index procedure.
  5. Subject with planned treatment of lesion involving aorto-ostial location.
  6. Subject with PCI of a non-target vessel within ± 30 days of the index procedure.
  7. Subject with history (within 6 months prior to index procedure) of (NYHA) class III or IV heart failure.
  8. Subject with history of active peptic ulcer or gastrointestinal bleeding within 6 months of the index procedure or other inability to comply with the recommended duration of dual antiplatelet therapy (DAPT).
  9. Subject is pregnant, breast-feeding or a woman of who plans pregnancy up to 1 year following index procedure.
  10. Subjects with current documented (LVEF) \< 30%.
  11. Subject is considered not able to tolerate at least 30 seconds of coronary occlusion for the target lesion treated.
  12. Subjects is currently participating in another drug or device study that has not completed primary endpoint follow-up.
  13. Subject with definite clinically active COVID-19 infection defined as a positive COVID test within 24 hours of index procedure.
  14. Subject has chronic renal insufficiency (dialysis dependent, or [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or had undergone renal transplantation.

PK Sub-Study Exclusion Criteria:

Subjects must meet none of the main protocol exclusion criteria to participate in the PK sub-study. Subjects will be excluded if any of the following additional PK sub-study exclusion criteria are met:

  1. Any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device has been placed/used in any part of the body within 3 months prior to the index procedure including non-target lesion(s) treated during the index procedure.
  2. Planned intervention with any limus family (Zotarolimus, Everolimus, Sirolimus etc.) eluting device anywhere in the body within 6 months after the index procedure. Note: staged procedures >30 days after index procedure (Exclusion #6 of the main protocol) are permitted only in the main protocol, and are not permitted in this PK sub-study.
  3. The subject is taking or has taken within the last 3 months any limus family medication(s) for any reason.
  4. Subject is concurrently enrolled in the main protocol angiographic registry.
  5. Subjects who are taking strong Inhibitors within 14 days before the index procedure or plan to take the strong inhibitors during the study period. Strong inhibitors include: cobicistat; ritonavir; indinavir and ritonavir; itraconazole; ketoconazole; lopinavir and ritonavir; paritaprevir and ritonavir and ombitasvir (and/or dasabuvir); posaconazole; saquinavir and ritonavir; tipranavir and ritonavir; elvitegravir and ritonavir; telithromycin; voriconazole; ceritinib; clarithromycin; idealalisib; nefazodone; nelfinavir.
  6. Subjects who are taking strong CYP3A4 Inducers within 14 days before the index procedure or plan to take the strong inducers during the study period. Strong inducers include apalutamide; carbamazepine; enzalutamide; ivosidenib; lumacaftor and ivacaftor; mitotane; phenytoin; rifampin; St. John's wort.

    • Angiographic Exclusion Criteria

Subject whose target lesion(s) meet any of the following angiographic criteria will be excluded from the trial:

  1. Target lesion is totally occluded or has evidence of thrombus.
  2. Target lesion is located in the left main or any arterial or venous graft.
  3. Target lesion is in a side branch that is "jailed" by a main vessel stent.
  4. In stent restenosis
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
960 participants (estimated)

Study arms

  • Experimental
    SELUTION SLR 014 PTCA DEB

    SELUTION Sustained Limus Release (SLR) 014 Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon (DEB) The SELUTION SLR 014 PTCA DEB is a minimally invasive, single use and sterile Sirolimus coated PTCA balloon catheter. The SELUTION SLR 014 PTCA DEB is available with balloon diameters from 2.0 to 3.0 mm and lengths of 15 to 40 mm for the purpose of the De Novo IDE trial

    Device: PCI with SELUTION SLR DCB

  • Active comparator
    Control Treatment

    any FDA approved "limus-based" Drug Eluting Stent, as per standard institutional practice

    Device: PCI with FDA approved "-limus" DES

Interventions

  • DevicePCI with SELUTION SLR DCB

    After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.

  • DevicePCI with FDA approved "-limus" DES

    For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices. The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B.

06

What researchers measure

Primary outcomes

  1. Target lesion failure (TLF)

    Target lesion failure (TLF) is defined as the composite of cardiac death, target-vessel myocardial infarction (MI) or clinically-driven target lesion revascularization (TLR) at 12 months. MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.

    Time frame: 12 months

  2. PK Sub-study Primary Endpoint 1

    PK parameters of C(max)

    Time frame: 6 months

  3. PK Sub-study Primary Endpoint 2

    PK parameters of T(max)

    Time frame: 6 months

  4. PK Sub-study Primary Endpoint 3

    PK parameters of AUC(last)

    Time frame: 6 months

  5. PK Sub-study Primary Endpoint 4

    PK parameters of MRT(last)

    Time frame: 6 months

Secondary outcomes

  1. Secondary Endpoint 1

    Composite of all-cause mortality, target vessel MI or clinically driven target lesion revascularization

    Time frame: 12 months

  2. Secondary Endpoint 2

    Lesion success, defined as attainment of \< 30% residual stenosis of target lesion using any percutaneous method

    Time frame: Up to 7 days

  3. Secondary Endpoint 3

    Procedure success, defined as attainment of \< 30% residual stenosis of the target lesion using the assigned study device only without the occurrence of in-hospital major adverse cardiac events (MACE), composite of all-cause death, MI or any clinically-driven TLR.

    Time frame: Up to 7 days

  4. Secondary Endpoint 4

    Composite safety endpoint, defined as the patient-oriented composite of any death, any MI (spontaneous or peri-procedural), or any repeat revascularization.

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  5. Secondary Endpoint 5

    All-Cause Mortality

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  6. Secondary Endpoint 6

    Cardiovascular Mortality

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  7. Secondary Endpoint 7

    MI (spontaneous MI using the 4th UDMI, peri-procedural MI using SCAI and Academic Research Consortium \[ARC\]-2 definitions)

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  8. Secondary Endpoint 8

    Clinically-driven TLR

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  9. Secondary Endpoint 9

    all TLR

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  10. Secondary Endpoint 10

    Clinically-driven Target Vessel Revascularization (TVR)

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  11. Secondary Endpoint 11

    all TVR

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  12. Secondary Endpoint 12

    Non-target lesion revascularization

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  13. Secondary Endpoint 13

    TLF

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  14. Secondary Endpoint 14

    Target vessel failure (TVF), defined as a composite of: cardiac death, target vessel MI (spontaneous or peri-procedural) and any clinically-driven TVR

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  15. Secondary Endpoint 15

    Stent or target lesion segment thrombosis (definite or probable) according to the ARC criteria for acute, subacute, late, very late and cumulative stent thrombosis

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

  16. Secondary Endpoint 16

    Bleeding Academic Research Consortium (BARC) class 2-5

    Time frame: 12 months

  17. Secondary Endpoint 17

    Net adverse clinical events, defined as death, MI (spontaneous or peri-procedural), TVR, stent/target lesion segment thrombosis or bleeding (BARC types 2-5, assessed to 12 months)

    Time frame: Up to 7 days and at 1 month, 6 months, 12 months, 2 years, 3 years, 4 years, and 5 years

Other outcomes

  1. PK Sub-Study Secondary Endpoint 1

    If calculations are valid, additional PK parameter of AUC(inf).

    Time frame: 6 months

  2. PK Sub-Study Secondary Endpoint 2

    If calculations are valid, additional PK parameter of Cl.

    Time frame: 6 months

  3. PK Sub-Study Secondary Endpoint 3

    If calculations are valid, additional PK parameter of Vz.

    Time frame: 6 months

  4. PK Sub-Study Secondary Endpoint 4

    If calculations are valid, additional PK parameter of Vss.

    Time frame: 6 months

  5. PK Sub-Study Secondary Endpoint 5

    If calculations are valid, additional PK parameter of half-life.

    Time frame: 6 months

  6. PK Sub-Study Secondary Endpoint 6

    Dose normalized C(max) will be considered if appropriate.

    Time frame: 6 months

  7. PK Sub-Study Secondary Endpoint 7

    Dose normalized AUC will be considered if appropriate.

    Time frame: 6 months

  8. PK Sub-Study Secondary Endpoint 8

    Device success, defined as attainment of ≤ 30% residual stenosis of the target lesion using the assigned device only

    Time frame: 6 months

07

Study locations

70 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Sep 2027, 47 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 47 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 14, 2023
StartActual
Oct 20, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2031
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05946629
Lead sponsor
M.A. Med Alliance S.A.
Collaborators
NAMSA, Cordis US Corp.
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Oct 20, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2031 (estimated)
Last update
Sep 24, 2026

Study contacts

Ron Waksman, MD
principal investigator · Medstar Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion